La cadena de opciones muestra datos clave de las opciones de acciones de Matinas BioPharma Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Matinas BioPharma Hldgs..

Matinas BioPharma Hldgs (AMEX:MTNB) Bolsa, Cadena de Opciones

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

WIIM

VF Corp shares are trading higher after the company announced financial targets at its investor day event.

GPRO

GoPro shares are trading lower. The company announced it approved a restructuring plan which includes a 26% workforce reduction.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading lower in possible reaction to Ozempic and Wegovy being listed as available by the FDA.

<p><strong>Enovix Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) shares are trading higher Wednesday following the company's better-than-expected third-quarter results. Enovix also announced a new development agreement with a leading smartphone OEM. Here&#8217;s what <a href="https://www.benzinga.com/news/earnings/24/10/41613274/enovix-stock-is-surging-after-the-bell-whats-going-on">you need to know.</a></p>
<p><strong>The Details:</strong> For the third quarter, Enovix reported revenue of $4.32 million, above estimates of $4.11 million. The company posted a loss of 17 cents per share, beating the estimated loss of 20 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p>Enovix CEO <strong>Raj Talluri</strong> highlighted the company&#8217;s progress, noting that Fab2 is now operational and shipping customer samples. The company&#8217;s key goals for the rest of 2024 include completing SAT for its High-Volume Line and delivering EX-2M samples.</p>
<p>For the fourth quarter, Enovix expects revenue between $8 million and $10 million, versus estimates of $7.38 million. The company expects an adjusted loss per share of 15 to 21 cents.</p>
<p><strong>What Else:</strong> In addition to the quarterly results, Enovix announced a development agreement with "one of the leading global smartphone OEMs with top five market share in China."</p>
<p>Enovix said it will develop a fully active silicon anode battery tailored for specific smartphone models under the new agreement, targeting a launch in the fourth quarter of 2025. Enovix said the agreement marks the company&#8217;s second deal with leading smartphone OEMs.</p>
<p>"The company now has agreements with two of the leading smartphone OEMs and has further sales momentum building in IoT and EV markets," the company said.</p>
<p>Benchmark analyst Michael Legg reiterated Enovix with a Buy and maintained a price target of $25 on Wednesday. Cantor Fitzgerald analyst Derek Soderberg reiterated an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> and price target of $30.</p>
<p><strong>ENVX Price Action</strong>: Enovix shares were up 5.41% at $11.21 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/10/41633104/alphabet-to-rally-around-33-here-are-10-top-analyst-forecasts-for-wednesday">Alphabet To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Earnings

News

Global

Movers

ENVX

What's Going On With Enovix Stock Today?

<p>BTIG  analyst Carl Reichardt   maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Buy and lowers the price target from $190 to $186.</p>


Price Target

Analyst Ratings

BTIG Maintains Buy on D.R. Horton, Lowers Price Target to $186

<p><strong>Apple Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) will likely highlight the performance of its iPhone 16 and upcoming product releases when the company reports fourth-quarter financial results <a href="https://www.benzinga.com/earnings">after market close Thursday. </a></p>
<p><strong>Earnings Estimates: </strong>Analysts expect  the Cupertino, California-based company to report fourth-quarter revenue of $94.56 billion, up from $89.5 billion in last year's fourth quarter, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1">from Benzinga Pro.</a></p>
<p>Apple has beaten analyst estimates for revenue in six straight quarters and nine of the last 10 quarters overall.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41591063/apple-will-be-the-first-to-hit-4-trillion-market-cap-milestone-says-dan-ives-as-hundreds-of-apps">Apple &#8216;Will Be The First To Hit&#8217; $4 Trillion Market Cap Milestone, Says Dan Ives As Hundreds Of Apps Will Be Built On AI Feature</a></strong></p>
<p>Analysts expect the company to report fourth-quarter earnings per share of $1.53, up from $1.46 reported in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in six straight quarters and nine of the last 10 quarters overall.</p>
<p><strong>What Analysts Are Saying:</strong> The iPhone 16 will be one of the key items analysts are watching in the earnings report and conference call.</p>
<p>"iPhone 16 demand has been relatively stable year-over-year and better-than-feared given more cautious data points around shorter lead-times relative to year-ago and production cuts," Goldman Sachs analyst Michael Ng <a href="https://www.benzinga.com/news/earnings/24/10/41554508/apple-q4-earnings-preview-goldman-sachs-analyst-anticipates-big-earnings-beat-resilient-iphone-16-d">recently said.</a></p>
<p>Ng reiterated a Buy rating on Apple with a $275 price target recently.</p>
<p>The analyst said Apple's push into artificial intelligence with Apple Intelligence could be a "long-term demand driver."</p>
<p>Another area Ng will be watching closely in Apple's report is the company's Services segment, which could be underestimated by investors.</p>
<p>"Apple&#8217;s installed base growth, secular growth in services, and new product innovation should more than offset cyclical headwinds to product revenue, such as a reduced iPhone unit demand due to a lengthening replacement cycle and reduced consumer demand for the PC &amp; tablet category."</p>
<p>Lower lead times for the iPhone 16 could signal a lack of demand for the newest version of the popular Apple smartphone, Morgan Stanley analyst Erik Woodring<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41350919/apple-analyst-predicts-a-september-quarter-revenue-beat-allays-fears-over-shorter-i"> recently said.</a></p>
<p>The analyst, who has an Overweight rating and $273 price target on Apple, said while the data for lead times was bad for the iPhone 16, it could be better than the previous iPhone 15.</p>
<p>Lower lead times could also be a factor of Apple being more proactive with its suppliers in keeping inventory in check to avoid supply constraints, Woodring said.</p>
<p>"We believe that better supply conditions are one of the contributing factors to why iPhone lead times are shorter this cycle than in recent cycles," Woodring said.</p>
<p>Here are other recent<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings"> analyst ratings on Apple </a>and their price targets:</p>
<ul>
<li>KeyBanc: Downgraded from Sector-weight to Underweight with $200 price target</li>
<li>Piper Sandler: Reiterated Neutral rating with $225 price target</li>
<li>Bank of America: Reiterated Buy rating with $256 price target</li>
<li>Barclays: Maintained Underweight rating with $186 price target</li>
</ul>
<p><strong>Key Items to Watch: </strong>All eyes will be on the iPhone 16 when Apple reports fourth-quarter results Thursday.</p>
<p>Other items that investors will be watching include Services, the initial rollout of Apple Intelligence and China.</p>
<ul>
<li>Services hit an<a href="https://www.benzinga.com/news/earnings/24/08/40116376/apple-q3-earnings-beat-expectations-tim-cook-highlights-breakthrough-ai-platform-installed-base-of-"> all-time record</a> for revenue in the third quarter but came in below Street estimates.</li>
<li>Weakness in China for the third quarter contributed to shares seeing downward pressure after the earnings results.</li>
<li>Apple&#8217;s recent <a href="https://www.benzinga.com/news/24/10/41582312/apples-introduces-imac-m4-chip-brings-faster-speeds-and-smarter-ai-features">AI product announcements</a> could be highlighted in the results as future catalysts.</li>
</ul>
<p><strong>Price Action: </strong>Apple stock is down 1% to $230.38 on Wednesday versus a 52-week trading range of $164.08 to $237.49. Apple stock is up 24% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/success-stories/24/10/41441641/apple-ceo-tim-cook-says-apple-intelligence-will-make-products-profoundly-different-new-ai-technol">Apple CEO Tim Cook Says New AI Technology Will Get Consumers &#8216;On A Different Technology Curve&#8217;</a></strong></li>
</ul>
<p><em>Image: </em></p>


Analyst Color

Previews

Reiteration

Tech

Trading Ideas

AAPL

Apple Q4 Earnings Preview: All Eyes On iPhone 16 Demand, Can Tech Giant Beat Analyst Estimates 7 Quarters Straight?

<p>Deep-pocketed investors have adopted a bearish approach towards Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MU usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 36 extraordinary options activities for Micron Technology. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 27% leaning bullish and 66% bearish. Among these notable options, 8 are puts, totaling $386,191, and 28 are calls, amounting to $1,631,443.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $250.0 for Micron Technology during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Micron Technology's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Micron Technology's whale trades within a strike price range from $80.0 to $250.0 in the last 30 days. </p>
<h3>Micron Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730315756_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.1</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$120.00</td>
<td>$287.5K</td>
<td>11.2K</td>
<td style="text-align: right;">711</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$6.15</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$250.00</td>
<td>$117.0K</td>
<td>331</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$11.5</td>
<td>$10.45</td>
<td>$10.55</td>
<td>$96.00</td>
<td>$105.5K</td>
<td>336</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$9.75</td>
<td>$9.6</td>
<td>$9.68</td>
<td>$96.00</td>
<td>$97.4K</td>
<td>336</td>
<td style="text-align: right;">302</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$9.7</td>
<td>$9.45</td>
<td>$9.53</td>
<td>$96.00</td>
<td>$95.2K</td>
<td>336</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Micron Technology</h3>
<p>Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.</p>
<p>Having examined the options trading patterns of Micron Technology, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Micron Technology's Current Market Status</h3>
<ul>
<li>Trading volume stands at 9,339,049, with MU's price down by -3.16%, positioned at $104.76.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 49 days.</li>
</ul>
<h3>What Analysts Are Saying About Micron Technology</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $142.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Micron Technology with a target price of $135.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $150. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Micron Technology with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Looking At Micron Technology's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>McKesson</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for McKesson.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 65% bullish and 35%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $538,721, and 12 are calls, for a total amount of $842,156.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $450.0 to $520.0 for McKesson during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for McKesson options trades today is 166.17 with a total volume of 3,049.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for McKesson's big money trades within a strike price range of $450.0 to $520.0 over the last 30 days.</p>
<h3>McKesson Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730315752_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$13.8</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$510.00</td>
<td>$253.1K</td>
<td style="text-align: right;">763</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$12.8</td>
<td>$12.0</td>
<td>$12.7</td>
<td>$507.50</td>
<td>$158.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.8</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$450.00</td>
<td>$106.5K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">72</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.9</td>
<td>$12.9</td>
<td>$14.7</td>
<td>$450.00</td>
<td>$94.0K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">136</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$15.7</td>
<td>$14.3</td>
<td>$14.6</td>
<td>$450.00</td>
<td>$87.6K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">196</td>
</tr>
</tbody>
</table>
</p>
<h3>About McKesson</h3>
<p>McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.</p>
<p>In light of the recent options history for McKesson, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of McKesson</h3>
<ul>
<li>Currently trading with a volume of 455,253, the MCK's price is up by 0.02%, now at $499.28. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 7 days.</li>
</ul>
<h3>What Analysts Are Saying About McKesson</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $630.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Leerink Partners persists with their Outperform rating on McKesson, maintaining a target price of $630. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for McKesson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


What the Options Market Tells Us About McKesson

<p>Deep-pocketed investors have adopted a bullish approach towards Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in C usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for Citigroup. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 66% leaning bullish and 29% bearish. Among these notable options, 4 are puts, totaling $161,279, and 20 are calls, amounting to $842,708.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $75.0 for Citigroup over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Citigroup's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Citigroup's whale activity within a strike price range from $40.0 to $75.0 in the last 30 days. </p>
<h3>Citigroup 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730315747_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/17/26</td>
<td>$5.75</td>
<td>$5.5</td>
<td>$5.6</td>
<td>$75.00</td>
<td>$95.1K</td>
<td>5.7K</td>
<td>0</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.15</td>
<td>$8.05</td>
<td>$8.15</td>
<td>$65.00</td>
<td>$66.0K</td>
<td>3.7K</td>
<td>85</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.07</td>
<td>$2.04</td>
<td>$2.05</td>
<td>$64.00</td>
<td>$57.1K</td>
<td>5.3K</td>
<td>551</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$1.06</td>
<td>$1.04</td>
<td>$1.06</td>
<td>$66.00</td>
<td>$53.4K</td>
<td>1.2K</td>
<td>568</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$1.06</td>
<td>$1.02</td>
<td>$1.06</td>
<td>$64.00</td>
<td>$53.0K</td>
<td>9.3K</td>
<td>3.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>After a thorough review of the options trading surrounding Citigroup, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Citigroup's Current Market Status</h3>
<ul>
<li>With a volume of 5,650,616, the price of C is down -0.12% at $64.61. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>What Analysts Are Saying About Citigroup</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $79.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Citigroup, targeting a price of $92.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Citigroup, which currently sits at a price target of $82.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Citigroup, which currently sits at a price target of $91.<br />
&#x2A; An analyst from Evercore ISI Group has decided to maintain their In-Line rating on Citigroup, which currently sits at a price target of $64.<br />
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Citigroup, which currently sits at a price target of $70. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Citigroup, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Market Whales and Their Recent Bets on Citigroup Options

<p>Scotiabank  analyst Mario Saric   maintains Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) with a Sector Outperform and raises the price target from $51.25 to $65.</p>


Scotiabank Maintains Sector Outperform on Brookfield, Raises Price Target to $65

Mirion Technologies shares are trading higher after the company reported better-than-expected Q3 earnings and raised its FY24 sales guidance.

<p>Scotiabank  analyst Mario Saric   maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Sector Outperform and raises the price target from $45.5 to $55.5.</p>


Scotiabank Maintains Sector Outperform on Brookfield Asset Mgmt, Raises Price Target to $55.5

<p>Scotiabank  analyst Maher Yaghi   maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Sector Outperform and lowers the price target from $248 to $236.</p>


Scotiabank Maintains Sector Outperform on American Tower, Lowers Price Target to $236

<p>On Tuesday, <strong>Novartis AG</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">consensus of $12.76 billion</a>.</p>
<p><strong>Guidance:</strong> Novartis also raised its 2024 full-year guidance again this year.</p>
<p>In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.</p>
<p>Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.</p>
<p>Pelabresib filing was further delayed, triggering a $800 million impairment charge related to the $2.9 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38497134/morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer" rel="noreferrer noopener">acquisition of MorphoSys</a>.</p>
<p>Earlier this year, MorphoSys faced&nbsp;a burgeoning safety concern surrounding&nbsp;pelabresib.</p>
<p><strong>Goldman Sachs</strong> notes that MorphoSys-related impairment charge is somewhat underwhelming, raising doubts about the company&#8217;s M&amp;A strategy.</p>
<p><strong>Truist </strong>notes that Novartis is concentrating on preparing the market for the PSMAFore label, which is expected to triple its addressable market.</p>
<p>They also pointed out that growth opportunities in China and Japan, and metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease, could push Pluvicto&#8217;s sales well above the projected $2 billion peak.</p>
<p>The company is committed to maximizing the potential of Pluvicto and its radioligand therapy (RLT) portfolio.</p>
<p>For other radiopharmaceutical companies targeting PSMA, entering this market may become more challenging.</p>
<p>A crucial question remains regarding the standards that must be met to compete with more effective radioligand products. This context relates to companies such as <strong>Eli Lilly And Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and <strong>Bristol Myers Squibb &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which have RLT products in their pipelines, as well as smaller companies, including <strong>Y-mAbs Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) and <strong>Perspective Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>).</p>
<p>Novartis highlighted continued strong growth and momentum and sees room to grow the market size for B-cell inhibition in multiple sclerosis, relating <strong>Biogen Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).</p>
<p>Truist highlights Novartis&#8217; strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few larger bolt-on acquisitions.</p>
<p>A Truist analyst indicated that they will be monitoring how the adoption of Leqvio may affect <strong>Amgen Inc</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Repatha and <strong>Regeneron Pharmaceuticals Inc</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Praluent. Meanwhile, Novartis has reported that the launch is advancing smoothly, and Leqvio continues to grow, outpacing the overall market as per the management.</p>
<p>Novartis&#8217; Cosentyx witnessed strong uptake and continued brand growth driven by hidradenitis suppurativa expansion, and the market opportunity can accommodate several players, <strong>Abbvie Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>), <strong>Incyte Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and <strong>Kymera Therapeutics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>).</p>
<p><strong>Price Action:</strong> NVS stock is down 0.48% at $110.00 at last check Wednesday.</p>
<p><em>Photo by Taljat David via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/10/41629995/orthopedic-implant-maker-zimmer-biomet-reports-better-than-expected-q3-earnings-updates-annual-fore" target="_blank" rel="noreferrer noopener">Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts</a></strong></li>
</ul>


Biotech

Equities

Large Cap

Health Care

General

ABBV

AMGN

BIIB

CATX

INCY

KYMR

REGN

YMAB

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

<p>BTIG  analyst Clark Lampen   maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and raises the price target from $114 to $142.</p>


BTIG Maintains Buy on Trade Desk, Raises Price Target to $142

<p>BTIG  analyst Ryan Zimmerman   maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $383 to $394.</p>


BTIG Maintains Buy on Stryker, Raises Price Target to $394

<p>Scotiabank  analyst Tomas Gonzalez   maintains Enel Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENIC#NYSE">ENIC</a>) with a Sector Outperform and lowers the price target from $4.4 to $3.9.</p>


ENIC

Scotiabank Maintains Sector Outperform on Enel Chile, Lowers Price Target to $3.9

<p>On Wednesday,&nbsp;<strong>Boston Scientific Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) released the results of the primary endpoint of the ACURATE IDE trial of&nbsp;ACURATE&nbsp;<em>neo2</em> Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41629382/acurate-neo2-aortic-valve-system-data-presented-at-late-breaking-clinical-trial-session-at-tct-202" rel="noreferrer noopener">open-heart surgery</a>.</p>
<p>The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.</p>
<p>This randomized trial evaluated the ACURATE&nbsp;<em>neo2</em> valve, the company&#8217;s second-generation transcatheter aortic valve replacement (TAVR) technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system.</p>
<p>SAPIEN valve is sold by <strong>Edwards Lifesciences Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and Evolut is <strong>Medtronic Plc&#8217;s</strong> NYSE: MDT) brand.</p>
<p>The composite rate of all-cause mortality, stroke, or rehospitalization at one year was 16.16% in the ACURATE&nbsp;<em>neo2</em> arm and 9.53% in the control arm, not meeting the prespecified criterion for non-inferiority (the posterior probability for non-inferiority was 77.9%, which is lower than the non-inferiority test threshold of 97.5%).</p>
<p>&#8220;This trial is the largest randomized comparison of TAVR platforms and was conducted over four years, including during a global pandemic that introduced complexities for enrollment,&#8221; said&nbsp;Michael Reardon, co-principal investigator of the ACURATE IDE trial.</p>
<p>The company also presented data from a post-hoc analysis to identify and evaluate expanded and under-expanded ACURATE&nbsp;<em>neo2</em> valve frames within the ACURATE IDE trial.</p>
<p>The company reviewed key procedural factors, including pre-and post-dilation, which help prepare for, enable, and confirm proper valve expansion during the procedure.</p>
<p>Following this review, an assessment of implant quality for the ACURATE&nbsp;<em>neo2</em> valve was initiated. The assessment highlighted that approximately 20% of the valves were under-expanded.</p>
<p>Data from the assessment also demonstrated that the rate of death, stroke, or rehospitalization at one year was similar between the ACURATE&nbsp;<em>neo2</em> expanded group and the control group.</p>
<p>Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S.</p>
<p>The ACURATE&nbsp;<em>neo2</em> Aortic Valve System and the ACURATE Prime Aortic Valve System are approved in Europe.</p>
<p>In the&nbsp;U.S., the ACURATE&nbsp;<em>neo2</em> Aortic Valve System and the ACURATE Prime Aortic Valve System are investigational devices.</p>
<p><strong>Price Action:</strong> BSX stock is down 1.66% at $83.16 at last check Wednesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/10/41630458/cdw-shares-dip-as-q3-sales-miss-amid-weak-hardware-demand-and-customer-delays" target="_blank" rel="noreferrer noopener">CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays</a></strong></li>
</ul>


Why is Boston Scientific Stock Trading Lower On Wednesday?

BMEA

Biomea Fusion shares are trading lower. The company reported Q3 financial results.

<p>BTIG  analyst Clark Lampen   maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $150 to $202.</p>


BTIG Maintains Buy on AppLovin, Raises Price Target to $202

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><a href="https://investorplace.com/stock-types/penny-stocks/">Penny stocks</a> to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word &ldquo;potential.&rdquo; That doesn&rsquo;t mean guaranteed &ndash; not by a long shot.</p>



<p>Indeed, let&rsquo;s talk about the dangers of this market subsector. While the low price of these securities tend to make them move on little (or even no) news, the opposite is also true. So, for example, if you put $10,000 into a 2-cent stock and it drops to 1 cent, guess what? You now have a position worth only $5,000.</p>



<p>That can be devastating for many investors who are lured into the arena on the promise of quick riches. Riches can happen, don&rsquo;t get me wrong. However, you&rsquo;re more likely to lose than to win statistically. Therefore, tight money management is an absolute must. If you can handle the heat, these penny stocks to buy might be right for you.</p>



<h2><br><br>Lilium (LILM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/09/lilm-stock-1-300x169.jpg" alt="The website for Lilium (LILM) is displayed on a smartphone screen."><div>Source: T. Schneider / Shutterstock.com</div></div><p>A specialist in the field of electric vertical takeoff and landing (eVTOL) aircraft, <strong>Lilium</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lilm-stock-quote/"><strong>LILM</strong></a>) understandably ranks among the most popular penny stocks to buy. That&rsquo;s evidenced by the consensus <a href="https://www.tipranks.com/stocks/lilm/forecast">moderate buy</a> view among Wall Street analysts. Further, the average price target calls for a rise to $2, which implies roughly 52% upside potential.</p>



<p>So, what&rsquo;s not to love? It&rsquo;s volatile. Sure, LILM stock gained about 12% of equity value recently. With that, it&rsquo;s up over 33% in the trailing 52 weeks. However, since making its public market debut, shares have lost 88%. That&rsquo;s not a great sign for the company obviously. At the same time, it&rsquo;s not as if the eVTOL sector is lighting up the board.</p>



<p>Further, another risk factor to keep in mind is that Lilium is a pre-revenue enterprise. That said, there is anticipated financial momentum. For fiscal 2024, covering experts believe that Lilium will post a loss of 59 cents per share, an improvement over last year&rsquo;s loss of 77 cents.</p>



<p>Most importantly, in fiscal 2025, they project revenue of $56.99 million. It&rsquo;s risky but that&rsquo;s the compelling nature of penny stocks to buy.</p>



<h2>BlackSky Technology (BKSY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/satellite-maxr-300x169.jpg" alt="(RKLB stock, space stocks) satellite over the Earth"><div>Source: Andrzej Puchta / Shutterstock.com</div></div><p>Based in Herndon, Virginia, <strong>BlackSky Technology</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/bksy-stock-quote/"><strong>BKSY</strong></a>) falls under the scientific and technical instruments category. <a href="https://finance.yahoo.com/quote/BKSY/profile">Per its public profile</a>, BlackSky provides geospatial intelligence, imagery and related data analytic products and services and mission systems. These systems include the development, integration and operation of satellite and ground systems for government and commercial customers in North America and other international markets.</p>



<p>As part of the burgeoning space economy, it&rsquo;s easy to see why BKSY is one of the penny stocks to buy. Financially, while the company has been all over the map in terms of earnings performance, it&rsquo;s been known to knock some balls out of the park. For example, it delivered earnings per share of one cent in the third quarter of last year. In contrast, the expected target was a loss of 12 cents.</p>



<p>For fiscal 2024, experts anticipate a loss of 33 cents per share on revenue of $110.76 million. That&rsquo;s a big step forward in terms of the top line, which was only $94.49 million in 2023. For those that can handle volatility risk, BKSY should be on your radar.</p>



<h2>Avino Silver &amp; Gold (ASM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/silver-mining-1600-300x169.jpg" alt="Macro of silver"><div>Source: Phawat / Shutterstock.com</div></div><p>Operating in the basic materials sector, <strong>Avino Silver &amp; Gold</strong> (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/asm-stock-quote/"><strong>ASM</strong></a>) features a business that&rsquo;s self-explanatory. It engages in the acquisition, exploration and advancement of mineral properties. Primarily, it explores for silver, gold and copper deposits. The former two assets naturally carry monetary policy implications as they&rsquo;re traditionally considered inflation hedges. The latter is a key metal to target if the global economy improves.</p>



<p>One factor that makes ASM a robust candidate for penny stocks to buy is the fear trade. With economic concerns juxtaposed with geopolitical flashpoints, investors have much to fret about. Gold can help but gold is also inconvenient to own. If you have a security like ASM stock, however, you can potentially enjoy secondary exposure to the yellow metal.</p>



<p>Even better, for fiscal 2024, analysts anticipate that EPS will hit four cents on revenue of $59.53 million. That&rsquo;s up from a breakeven year in 2023 and sales of $43.89 million. Looking out to fiscal 2025, EPS could rise to 7 cents on sales of $69.03 million.</p>



<h2>Hookipa Pharma (HOOK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Operating in the broader healthcare space, <strong>Hookipa Pharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hook-stock-quote/"><strong>HOOK</strong></a>) falls under the biotechnology umbrella. <a href="https://finance.yahoo.com/quote/HOOK/profile">Per its corporate profile</a>, Hookipa is a clinical-stage enterprise that is developing immunotherapeutics targeting infectious diseases and cancers based on the company&rsquo;s proprietary arenavirus platform. Its lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab, which is in a Phase 2 trial.</p>



<p>Notably, Hookipa enjoys a collaboration with <strong>Gilead Sciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/"><strong>GILD</strong></a>). This effort focuses on preclinical research programs to evaluate potential vaccine products for the treatment, diagnosis or prevention of the hepatitis B virus. Hookipa features variable earnings performances. However, in Q1 2024, it posted EPS of 11 cents against an expected loss per share of 10 cents.</p>



<p>For fiscal 2024, experts project a loss per share of 34 cents on revenue of $55.47 million. That&rsquo;s a massive improvement over last year&rsquo;s loss of 86 cents per share on sales of only $20.13 million. Therefore, it could be one of the worthwhile penny stocks to buy. Do note, though, that HOOK is volatile, losing 46% in the past 52 weeks.</p>



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/kscp-stock-300x169.png" alt="An image of a Knightscope, Inc. (KSCP) robot in a parking garage"><div>Source: Sundry Photography / Shutterstock.com</div></div><p>An enticing (albeit extremely risky) idea for penny stocks to buy, <strong>Knightscope</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/"><strong>KSCP</strong></a>) deserves a look for anyone with some pocket change they want to use rather than throwing it in the wishing fountain. Specializing in autonomous security robots (ASRs), Knightscope could potentially change the game regarding security and law enforcement. Essentially, the company deploys robots as front-line security patrol operators.</p>



<p>This directive features myriad advantages over the traditional deployment of human officers. First and foremost, Knightscope addresses the safety concern. In a volatile situation, it&rsquo;s usually better to send a robot in because it&rsquo;s replaceable. Second, robots being non-human can sidestep the sometimes tricky situation involving security forces and community interactions.</p>



<p>Financially, Knightscope&rsquo;s performances are all over the map. However, in fiscal 2024, analysts anticipate the stats to tighten up. The company could generate a loss of 19 cents per share on revenue of $15.9 million. That&rsquo;s a big improvement over last year&rsquo;s results of a loss of 34 cents on sales of $12.8 million. Again, it&rsquo;s risky but Ascendiant&rsquo;s Edward Woo rates it a &ldquo;buy&rdquo; with a <a href="https://www.tipranks.com/stocks/kscp/forecast">$4.25 price target</a>.</p>



<h2>Arqit Quantum (ARQQ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/06/cybersecurity-stocks-300x169.jpg" alt="A man sitting in front of a computer"><div>Source: Shutterstock</div></div><p>Based in London, U.K., <strong>Arqit Quantum</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/arqq-stock-quote/"><strong>ARQQ</strong></a>) falls under the infrastructure software category. <a href="https://finance.yahoo.com/quote/ARQQ/profile/">According to its public profile</a>, the company provides cybersecurity services through satellite and terrestrial platforms. It offers <a href="https://arqit.uk">QuantumCloud</a>, a Platform as a Service (PaaS) that allegedly creates unbreakable software encryption keys. Thus, it&rsquo;s a marriage of two compelling industries: cybersecurity and quantum computing.</p>



<p>Naturally, ARQQ makes an enticing case for penny stocks to buy due to the underlying relevance. It&rsquo;s not just about burgeoning interest in anything quantum related. Rather, the threat of digital hacks and breaches is only rising. It seems like every year, some major enterprise or organization suffers a significant compromising of its data, impacting both the business and its customers.</p>



<p>Cynically, then, Arqit benefits from a potentially permanent bullish narrative. How does that translate on paper? For fiscal 2024, experts believe the company will post a loss per share of 12 cents on revenue of $20.04 million. Last year, the company&rsquo;s results sat at a loss of 33 cents on sales of $693,000.</p>



<h2>Matinas BioPharma (MTNB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p>Headquartered in Bedminster, New Jersey, <strong>Matinas BioPharma</strong> (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/mtnb-stock-quote/"><strong>MTNB</strong></a>) also falls under the biotechnology umbrella. <a href="https://finance.yahoo.com/quote/MTNB/profile">According to its corporate profile</a>, Matinas is a clinical-stage enterprise that identifies and develops pharmaceutical products using its lipid nanocrystal (<a href="https://investorplace.com/stock-quotes/lnc-stock-quote/"><strong>LNC</strong></a>) platform technology. This innovation allows for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins and peptides.</p>



<p>Currently, the company&rsquo;s <a href="https://www.matinasbiopharma.com/lnc-technology/mat2203-expanded-access-policy#:~:text=One%20of%20the%20Company's%20lead,(LNC)%20platform%20delivery%20technology.">lead product candidate is MAT2203</a>, an oral formulation that is currently in Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis. The drug candidate also aims to prevent invasive fungal infections in patients due to immunosuppressive therapy. Analysts rate shares a <a href="https://www.tipranks.com/stocks/mtnb/forecast">consensus moderate buy</a> with an 80-cent price target, implying almost 364% upside potential.</p>



<p>Of course, with such a massive profit target, you&rsquo;ve got to expect wild volatility. And that&rsquo;s the case with MTNB stock. Since the start of the year, shares lost 25% of equity value. In the past 52 weeks, they&rsquo;re down nearly 61%.</p>



<p>Still, if the clinical trials evolve successfully, MTNB could be huge. It&rsquo;s one of the penny stocks to buy (or at least to watch).</p>



<p><strong><em>On Penny Stocks and Low-Volume Stocks:&#8239;</em></strong><em>With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.</em></p>



<p><strong><em>Read More:&#8239;</em></strong><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/penny-stock-sleepers-7-under-the-radar-gems-ready-to-launch/">Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Matinas BioPharma (MTNB – Research Report). The associated price target r...

Buy Rating Affirmed for Matinas BioPharma's Drug MAT2203 Amid Successful Treatments and Pivotal Phase 3 Study

Matinas Biopharma Q2 2024 Earnings Preview

Matinas Biopharma GAAP EPS of -$0.02 beats by $0.01

Matinas BioPharma Holdings, Inc. 2024 Q2 - Results - Earnings Call Presentation

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Matinas BioPharma Hldgs</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/mtnb-stock-quote/"><strong>MTNB</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Matinas BioPharma Hldgs reported earnings per share of -2 cents. This met the analyst estimate for EPS of -2 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/mtnb-stock-earnings-matinas-biopharma-hldgs-for-q2-of-2024/">MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024

Matinas BioPharma (MTNB) has provided an update. The Company has updated its corporate presentation for use at upcoming conferences and investor me...

Matinas BioPharma Releases Updated Corporate Presentation

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price...

Buy Rating Affirmed: Matinas BioPharma's Solid Financials and Promising Drug Development

These are the upcoming stock splits for the week of September 2 to September 6, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a c...

Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested

ARQQ

BKSY

DPRO

GILD

HOOK

KSCP

LILM

MTNB

WRIV

Press Releases

Matinas BioPharma Prices $10 Million Registered Direct Offering

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Comments

Matinas BioPharma Hldgs

Matinas BioPharma Hldgs (MTNB) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL